RxDoctor Payments DataLook up a doctor →

Eddie Rodriguez Castro, MD

Nephrology · Toa Baja, PRNPI 1760740849

Payments from drug & device makers

$591,416in general payments, 2019–2025

Across 915 payments — averaging $646.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$180K
  • Amgen$105K
  • Bayer$95K
  • GSK$71K
  • Travere Therapeutics, Inc.$69K
  • ANI Pharmaceuticals, Inc.$23K
  • plus $49K from 27 others

What the payments were for

  • Consulting fees$19,8783%
  • Speaking & faculty fees$512,63887%
  • Travel & lodging$23,9464%
  • Food & beverage$34,6976%
  • Education$2560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$591,416 in reported general payments places this provider in the 95th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$22,649
Medicare patients
49
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol903$1,095,980
JardianceEmpagliflozin283$320,312
KerendiaFinerenone354$284,791
BenlystaBelimumab36$187,820
OzempicSemaglutide160$159,973
TrulicityDulaglutide71$81,103
Xigduo XrDapaglifloz Propaned/Metformin55$75,534
LokelmaSodium Zirconium Cyclosilicate68$69,121
RybelsusSemaglutide19$29,925
Synjardy XrEmpagliflozin/Metformin Hcl22$28,658
JanuviaSitagliptin Phosphate18$24,090
Sevelamer Carbonate132$24,032
XareltoRivaroxaban23$22,313
Calcium Acetate201$20,189
EliquisApixaban23$19,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$179,880$1,165,101971 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi$808$378,752339 claims
BayerKerendia$94,880$284,791354 claims
Novo NordiskOzempic, Rybelsus$444$189,898179 claims
GSKBenlysta$70,744$187,82036 claims
Lilly USA, LLCTrulicity, Humalog$353$87,112113 claims
Johnson & JohnsonXarelto$17,521$22,31323 claims
ANI Pharmaceuticals, Inc.Valsartan$22,824$87215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Toa Baja

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →